{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT02632448",
            "orgStudyIdInfo": {
                "id": "ESPS-001"
            },
            "organization": {
                "fullName": "Esperas Pharma Inc.",
                "class": "OTHER"
            },
            "briefTitle": "A Study of LY2880070 in Participants With Advanced or Metastatic Cancer",
            "officialTitle": "A Phase 1b/2a Three-Part Open-Label Multicenter Study to Evaluate the Safety and Efficacy of LY2880070 as Monotherapy and in Combination With Gemcitabine in Patients With Advanced or Metastatic Cancer",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Other"
            ],
            "study": "a-study-of-in-participants-with-advanced-or-metastatic-cancer"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-03",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2016-05-16",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-09-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-09-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2015-12-14",
            "studyFirstSubmitQcDate": "2015-12-15",
            "studyFirstPostDateStruct": {
                "date": "2015-12-16",
                "type": "ESTIMATED"
            },
            "lastUpdateSubmitDate": "2024-03-27",
            "lastUpdatePostDateStruct": {
                "date": "2024-03-29",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Esperas Pharma Inc.",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The main purpose of this 3-part study is to evaluate the safety and efficacy of the study drug known as LY2880070 in participants with advanced or metastatic solid tumors."
        },
        "conditionsModule": {
            "conditions": [
                "Solid Tumors",
                "Colorectal Cancer",
                "Breast Cancer",
                "Ovarian Cancer",
                "Colon Cancer",
                "Rectal Cancer",
                "Neoplasms",
                "Endometrial Cancer",
                "Soft Tissue Sarcoma",
                "Triple Negative Breast Cancer",
                "Pancreas Cancer",
                "Pancreatic Cancer"
            ],
            "keywords": [
                "Metastatic cancer",
                "Advanced cancer",
                "Recurrent cancer",
                "Colorectal neoplasms",
                "Triple negative breast cancer",
                "Ovarian neoplasms",
                "Colon neoplasms",
                "Rectal neoplasms",
                "Triple negative breast neoplasms",
                "Gastrointestinal stromal tumor",
                "Pancreatic Neoplasms",
                "Pancreatic Cancer"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "BASIC_SCIENCE",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 229,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Part A: LY2880070",
                    "type": "EXPERIMENTAL",
                    "description": "Multiple oral doses of LY2880070 during 21-day cycles",
                    "interventionNames": [
                        "Drug: LY2880070"
                    ]
                },
                {
                    "label": "Part A: LY2880070 with Gemcitabine",
                    "type": "EXPERIMENTAL",
                    "description": "Multiple oral doses of LY2880070, and Gemcitabine administered intravenously during 21-day cycles",
                    "interventionNames": [
                        "Drug: LY2880070",
                        "Drug: Gemcitabine"
                    ]
                },
                {
                    "label": "Part A: LY2880070 (Metabolism Phenotype)",
                    "type": "EXPERIMENTAL",
                    "description": "Multiple oral doses of LY2880070 administered during 21 day cycles, to participants who are poor metabolizers",
                    "interventionNames": [
                        "Drug: LY2880070"
                    ]
                },
                {
                    "label": "Part B: LY2880070 and Gemcitabine (Breast)",
                    "type": "EXPERIMENTAL",
                    "description": "Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)",
                    "interventionNames": [
                        "Drug: LY2880070",
                        "Drug: Gemcitabine"
                    ]
                },
                {
                    "label": "Part B: LY2880070 and Gemcitabine (Colorectal)",
                    "type": "EXPERIMENTAL",
                    "description": "Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)",
                    "interventionNames": [
                        "Drug: LY2880070",
                        "Drug: Gemcitabine"
                    ]
                },
                {
                    "label": "Part B:LY2880070 and Gemcitabine (Ovarian)",
                    "type": "EXPERIMENTAL",
                    "description": "Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)",
                    "interventionNames": [
                        "Drug: LY2880070",
                        "Drug: Gemcitabine"
                    ]
                },
                {
                    "label": "Part B: LY2880070 and Gemcitabine (Endometrial)",
                    "type": "EXPERIMENTAL",
                    "description": "Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)",
                    "interventionNames": [
                        "Drug: LY2880070",
                        "Drug: Gemcitabine"
                    ]
                },
                {
                    "label": "Part B: LY2880070 and Gemcitabine (Soft Tissue Sarcoma (STS))",
                    "type": "EXPERIMENTAL",
                    "description": "Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)",
                    "interventionNames": [
                        "Drug: LY2880070",
                        "Drug: Gemcitabine"
                    ]
                },
                {
                    "label": "Part B: LY2880070 and Gemcitabine (Pancreatic)",
                    "type": "EXPERIMENTAL",
                    "description": "Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)",
                    "interventionNames": [
                        "Drug: LY2880070",
                        "Drug: Gemcitabine"
                    ]
                },
                {
                    "label": "Part C: LY2880070 and Gemcitabine (High Grade Serous Ovarian Cancer)",
                    "type": "EXPERIMENTAL",
                    "description": "Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)",
                    "interventionNames": [
                        "Drug: LY2880070",
                        "Drug: Gemcitabine"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "LY2880070",
                    "description": "Capsules",
                    "armGroupLabels": [
                        "Part A: LY2880070",
                        "Part A: LY2880070 (Metabolism Phenotype)",
                        "Part A: LY2880070 with Gemcitabine",
                        "Part B: LY2880070 and Gemcitabine (Breast)",
                        "Part B: LY2880070 and Gemcitabine (Colorectal)",
                        "Part B: LY2880070 and Gemcitabine (Endometrial)",
                        "Part B: LY2880070 and Gemcitabine (Pancreatic)",
                        "Part B: LY2880070 and Gemcitabine (Soft Tissue Sarcoma (STS))",
                        "Part B:LY2880070 and Gemcitabine (Ovarian)",
                        "Part C: LY2880070 and Gemcitabine (High Grade Serous Ovarian Cancer)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Gemcitabine",
                    "description": "50 to 600 milligrams per square meter of body surface area (mg/m2)",
                    "armGroupLabels": [
                        "Part A: LY2880070 with Gemcitabine",
                        "Part B: LY2880070 and Gemcitabine (Breast)",
                        "Part B: LY2880070 and Gemcitabine (Colorectal)",
                        "Part B: LY2880070 and Gemcitabine (Endometrial)",
                        "Part B: LY2880070 and Gemcitabine (Pancreatic)",
                        "Part B: LY2880070 and Gemcitabine (Soft Tissue Sarcoma (STS))",
                        "Part B:LY2880070 and Gemcitabine (Ovarian)",
                        "Part C: LY2880070 and Gemcitabine (High Grade Serous Ovarian Cancer)"
                    ],
                    "otherNames": [
                        "Gemzar"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Maximum Tolerated Dose(s)",
                    "timeFrame": "Baseline through Cycle 1 (Estimated up to 21 days)"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Number of dose limiting toxicities (DLTs)",
                    "timeFrame": "Baseline through Cycle 1 (Estimated up to 21 days)"
                },
                {
                    "measure": "Area under the plasma concentration versus time curve from time zero to 24 hours post-dose (AUC0-24)",
                    "timeFrame": "Baseline to 24-hours post dose (up to Day 20 in Cycle 1)"
                },
                {
                    "measure": "Peak plasma concentration (Cmax)",
                    "timeFrame": "Baseline to 24 hours post-dose (up to Day 20 in Cycle 1)"
                },
                {
                    "measure": "Time to reach maximum plasma concentration (tmax)",
                    "timeFrame": "Baseline to 24 hours post dose (up to Day 20 in Cycle 1)"
                },
                {
                    "measure": "Change from baseline in white blood cell count",
                    "timeFrame": "Baseline to 24 hours post dose (up to Day 20 in Cycle 1)"
                },
                {
                    "measure": "Change from baseline in neutrophil count",
                    "timeFrame": "Baseline to 24 hours post dose (up to Day 20 in Cycle 1)"
                },
                {
                    "measure": "Change from baseline in lymphocyte count",
                    "timeFrame": "Baseline to 24 hours post dose (up to Day 20 in Cycle 1)"
                },
                {
                    "measure": "Number of participants with tumor response (objective response rate) as measured by the Response Evaluable Criteria in Solid Tumors (RECIST v.1.1)",
                    "timeFrame": "Baseline to study completion (estimated up to 4 years)"
                },
                {
                    "measure": "Duration of objective response",
                    "timeFrame": "Baseline to study completion (estimated up to 4 years)"
                },
                {
                    "measure": "Best response",
                    "timeFrame": "Baseline to study completion (estimated up to 4 years)"
                },
                {
                    "measure": "Progression free survival",
                    "timeFrame": "Baseline to study completion (estimated up to 4 years)"
                },
                {
                    "measure": "Overall survival",
                    "timeFrame": "Baseline up to 1 year"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale\n* Have an estimated life expectancy of greater than or equal to (\u2265)12 weeks\n* Have adequate organ function\n* Have received 1-4 prior systemic therapies for locally advanced or metastatic disease\n* Agree to use medically approved contraceptives during the study and for 3 months following the last study treatment\n* All females must have a negative serum pregnancy test result, and females of child-bearing potential must have a negative urine pregnancy test result, prior to the first study treatment\n* Have tumor lesions considered measurable by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\n* Must be, in the judgment of the investigator, an appropriate candidate for experimental therapy, and no standard therapy would confer clinical benefit\n\nFor Part A\n\n* Must have evidence of cancer (solid tumors, excluding glioblastoma and primary brain tumor) that is advanced or metastatic\n* For the Metabolism Phenotype Arm in Part A, participants must have a Cytochrome P450 (CYP2D6) poor metabolizer phenotype\n\nFor Part B\n\n* Have advanced or metastatic colorectal cancer, triple negative breast cancer (per American Society of Clinical Oncology-College of American Pathology guidelines), epithelial ovarian cancer, endometrial, soft tissue sarcoma, pancreatic cancer\n\n  * For TNBC:\n\n    * Recurrent/refractory Triple Negative Breast Cancer (TNBC) defined as any beast cancer that expresses \\<1% estrogen receptor (ER) and \\<1% progesterone receptor (PR) and is Her2 negative\n  * For Colorectal (CRC):\n\n    * Must have histologically confirmed advanced or metastatic colorectal cancer\n  * For Ovarian Cancer:\n\n    * Must have histologically confirmed advanced or metastatic epithelial ovarian cancer\n    * Must be eligible to receive Gemzar (GEM) and not refractory to GEM/carboplatin\n    * Must have the ability to tolerate GEM\n    * May have received GEM as previous therapy\n  * For Endometrial cancer:\n\n    * Must have histologically confirmed endometrial cancer that is metastatic or locally advanced\n    * Must have failed at least 1 prior chemotherapy\n  * For STS:\n\n    * Must have histologically confirmed STS that is metastatic or locally advanced\n    * Patients with gastrointestinal stromal tumors (GIST) must have failed a KIT inhibitor\n    * Must have failed at least 1 prior chemotherapy\n  * For Pancreatic Cancer:\n\n    * Must have histologically confirmed pancreatic cancer that is metastatic or locally advanced\n    * Must have failed at least 1 prior chemotherapy regimen\n  * For Part C\n  * Participants with high grade serous ovarian cancer (HGSOC) will be screened for specific genetic signatures\n\nExclusion Criteria:\n\n* Have received treatment with an investigational drug which has not received regulatory approval within 21 days of first study treatment\n* Have symptomatic central nervous system (CNS) metastasis\n* Females who are pregnant or nursing\n* Have known positive test results of human immunodeficiency virus, or have chronic active hepatitis A, B or C\n* Have a corrected QT interval (QTcB) greater than (\\>) 470 milliseconds (msec) (female) or \\>450 msec (male), or a history of congenital long QT syndrome\n* Have had a bone marrow transplant\n* Have participated in this study, or are currently enrolled in another clinical study of an investigational medicinal product\n* Have had radiation therapy to \\>25% of bone marrow\n* For Part B\n\n  * Have a history of another active cancer within the past year, except cervical cancer in situ, in situ carcinoma of the bladder, basal cell carcinoma of the skin, or another in situ carcinoma that is considered cured",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Esperas Pharma Inc.",
                    "role": "CONTACT"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Email: Darcy.Vincett@ozmosisresearch.ca",
                    "affiliation": "Esperas Pharma Inc.",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Dana Farber Cancer Institute",
                    "status": "COMPLETED",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02215",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Karmanos Cancer Institute",
                    "status": "COMPLETED",
                    "city": "Detroit",
                    "state": "Michigan",
                    "zip": "48201",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.33143,
                        "lon": -83.04575
                    }
                },
                {
                    "facility": "Tom Baker Cancer Centre",
                    "status": "RECRUITING",
                    "city": "Calgary",
                    "state": "Alberta",
                    "zip": "T2N 4N2",
                    "country": "Canada",
                    "contacts": [
                        {
                            "name": "Temitope Oke",
                            "role": "CONTACT",
                            "phone": "403-521-3226",
                            "email": "Temitope.Oke@albertahealthservices.ca"
                        },
                        {
                            "name": "Prafull Ghatage",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 51.05011,
                        "lon": -114.08529
                    }
                },
                {
                    "facility": "Cross Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Edmonton",
                    "state": "Alberta",
                    "zip": "T6G 1Z2",
                    "country": "Canada",
                    "contacts": [
                        {
                            "name": "Trish Mhonde",
                            "role": "CONTACT",
                            "phone": "(780) 432-8647",
                            "email": "trish.mhonde@albertahealthservices.ca"
                        },
                        {
                            "name": "Quincy Chu",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 53.55014,
                        "lon": -113.46871
                    }
                },
                {
                    "facility": "BC Cancer Agency",
                    "status": "RECRUITING",
                    "city": "Vancouver",
                    "state": "British Columbia",
                    "zip": "V5Z 4E6",
                    "country": "Canada",
                    "contacts": [
                        {
                            "name": "Joanne Marshall",
                            "role": "CONTACT",
                            "phone": "604-877-600 X 675851",
                            "email": "joanne.marshall@bccancer.bc.ca"
                        },
                        {
                            "name": "Yvette Drew",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 49.24966,
                        "lon": -123.11934
                    }
                },
                {
                    "facility": "Ottawa Hospital Cancer Centre",
                    "status": "COMPLETED",
                    "city": "Ottawa",
                    "state": "Ontario",
                    "zip": "K1H 8L6",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 45.41117,
                        "lon": -75.69812
                    }
                },
                {
                    "facility": "University Health Network - Princess Margaret Hospital",
                    "status": "RECRUITING",
                    "city": "Toronto",
                    "state": "Ontario",
                    "zip": "M5G 2M9",
                    "country": "Canada",
                    "contacts": [
                        {
                            "name": "Horace Wong",
                            "role": "CONTACT",
                            "phone": "416-946-4501",
                            "phoneExt": "3452",
                            "email": "horace.wong@uhn.ca"
                        },
                        {
                            "name": "Amit Oza",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.70011,
                        "lon": -79.4163
                    }
                },
                {
                    "facility": "Jewish General Hospital",
                    "status": "RECRUITING",
                    "city": "Montreal",
                    "state": "Quebec",
                    "zip": "H3T 1E2",
                    "country": "Canada",
                    "contacts": [
                        {
                            "name": "Alessandra Figueiredo de Vasconcelos",
                            "role": "CONTACT",
                            "phone": "514-340-8222",
                            "phoneExt": "26823",
                            "email": "alessandra.figueiredo.devasconcelos.ccomtl@ssss.gouv.qc.ca"
                        },
                        {
                            "name": "Wilson Miller",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 45.50884,
                        "lon": -73.58781
                    }
                },
                {
                    "facility": "McGill University Health Centre",
                    "status": "RECRUITING",
                    "city": "Montreal",
                    "state": "Quebec",
                    "zip": "H4A 3J1",
                    "country": "Canada",
                    "contacts": [
                        {
                            "name": "Lucy Gilbert",
                            "role": "CONTACT",
                            "phone": "514-934-1934",
                            "phoneExt": "34049"
                        },
                        {
                            "name": "Mohamed Bakir",
                            "role": "CONTACT",
                            "phone": "514 934-1934",
                            "phoneExt": "23980",
                            "email": "mohamed.bakir@muhc.mcgill.ca"
                        },
                        {
                            "name": "Lucy Gilbert",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 45.50884,
                        "lon": -73.58781
                    }
                },
                {
                    "facility": "Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al",
                    "status": "RECRUITING",
                    "city": "Montr\u00e9al",
                    "state": "Quebec",
                    "zip": "H2X 0A9",
                    "country": "Canada",
                    "contacts": [
                        {
                            "name": "Diane Provencher",
                            "role": "CONTACT",
                            "phone": "514-890-8444",
                            "email": "diane.provencher.chum@ssss.gouv.qc.ca"
                        },
                        {
                            "name": "Diane Provencher",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 45.50884,
                        "lon": -73.58781
                    }
                },
                {
                    "facility": "General Hospital Zadar",
                    "status": "RECRUITING",
                    "city": "Zadar",
                    "zip": "23000",
                    "country": "Croatia",
                    "contacts": [
                        {
                            "name": "Sara Bili\u0107 Kne\u017eevi\u0107",
                            "role": "CONTACT",
                            "phone": "+38523505064",
                            "email": "sarabilicknezevic@yahoo.com"
                        },
                        {
                            "name": "Sara Bili\u0107 Kne\u017eevi\u0107",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 44.11972,
                        "lon": 15.24222
                    }
                },
                {
                    "facility": "University Hospital Centre Zagreb",
                    "status": "RECRUITING",
                    "city": "Zagreb",
                    "zip": "10000",
                    "country": "Croatia",
                    "contacts": [
                        {
                            "name": "Prim. Vi\u0161nja Matkovi\u0107",
                            "role": "CONTACT",
                            "phone": "+385146048701",
                            "email": "visnja.matko@gmail.com"
                        },
                        {
                            "name": "Prim. Vi\u0161nja Matkovi\u0107",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 45.81444,
                        "lon": 15.97798
                    }
                },
                {
                    "facility": "Centrum Onkologii im. prof. F. \u0141ukaszczyka",
                    "status": "RECRUITING",
                    "city": "Bydgoszcz",
                    "zip": "85-796",
                    "country": "Poland",
                    "contacts": [
                        {
                            "name": "Bogdan Zurawski",
                            "role": "CONTACT",
                            "phone": "+48 52 374 31 09",
                            "email": "bzur1@wp.pl"
                        },
                        {
                            "name": "Bogdan Zurawski",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 53.1235,
                        "lon": 18.00762
                    }
                },
                {
                    "facility": "Uniwersyteckie Centrum Kliniczne Osrodek Badan Klinicznych Wczesnych Faz",
                    "status": "RECRUITING",
                    "city": "Gda\u0144sk",
                    "zip": "80-214",
                    "country": "Poland",
                    "contacts": [
                        {
                            "name": "Dagmara Klasa-Mazurkiewicz",
                            "role": "CONTACT",
                            "phone": "+48 58 584 40 50/47",
                            "email": "dklasa@gumed.edu.pl"
                        },
                        {
                            "name": "Dagmara Klasa-Mazurkiewicz",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 54.35205,
                        "lon": 18.64637
                    }
                },
                {
                    "facility": "Centrum Bada\u0144 Klinicznych Jagiello\u0144skie Centrum Innowacji sp. z o. o.",
                    "status": "RECRUITING",
                    "city": "Krak\u00f3w",
                    "zip": "30-348",
                    "country": "Poland",
                    "contacts": [
                        {
                            "name": "Pawel Blecharz",
                            "role": "CONTACT",
                            "phone": "+48126348238",
                            "email": "pawel.blecharz@interia.pl"
                        },
                        {
                            "name": "Pawel Blecharz",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 50.06143,
                        "lon": 19.93658
                    }
                },
                {
                    "facility": "Szpital Specjalistyczny im. L. Rydygiera w Krakowie sp. z o. o.",
                    "status": "RECRUITING",
                    "city": "Krak\u00f3w",
                    "zip": "31-826",
                    "country": "Poland",
                    "contacts": [
                        {
                            "name": "Marek Jasiowka",
                            "role": "CONTACT",
                            "phone": "+48(12)6468634",
                            "email": "mjasiowka.bk@rydygierkrakow.pl"
                        },
                        {
                            "name": "Marek Jasiowka",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 50.06143,
                        "lon": 19.93658
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "type": "RESULT",
                    "citation": "W.H. Miller, A.F. Shields, D. Provencher, L. Gilbert, G. Shapiro, A.M. Oza, J. Spratlin, S. Lheureux, G. Bhat, S. Salvador, P. Nunes, S. Lau, I. Weiner, J. Keene, S. Zaknoen, P. Smith, J. Stille, D. Vincett, Q.S-C. Chu, 537P A phase I/II study of oral chk1 inhibitor LY2880070 in combination with low-dose gemcitabine in patients with advanced or metastatic ovarian cancer, Annals of Oncology, Volume 33, Supplement 7, 2022, Pages S793-S794, ISSN 0923-7534, https://doi.org/10.1016/j.annonc.2022.07.665. (https://www.sciencedirect.com/science/article/pii/S0923753422025169)"
                },
                {
                    "type": "RESULT",
                    "citation": "DOI: 10.1200/JCO.2020.38.15_suppl.3579 Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 3579-3579."
                },
                {
                    "type": "RESULT",
                    "citation": "DOI: 10.1200/JCO.2020.38.15_suppl.3581 Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 3581-3581."
                }
            ],
            "seeAlsoLinks": [
                {
                    "label": "A phase 1b study of oral chk1 inhibitor LY2880070 in combination with gemcitabine in patients with advanced or metastatic cancer: Abstract 2020 ASCO Annual Meeting",
                    "url": "http://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.3581"
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000001943",
                    "term": "Breast Neoplasms"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000010190",
                    "term": "Pancreatic Neoplasms"
                },
                {
                    "id": "D000012509",
                    "term": "Sarcoma"
                },
                {
                    "id": "D000016889",
                    "term": "Endometrial Neoplasms"
                },
                {
                    "id": "D000064726",
                    "term": "Triple Negative Breast Neoplasms"
                },
                {
                    "id": "D000009362",
                    "term": "Neoplasm Metastasis"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000001941",
                    "term": "Breast Diseases"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                },
                {
                    "id": "D000004067",
                    "term": "Digestive System Neoplasms"
                },
                {
                    "id": "D000004066",
                    "term": "Digestive System Diseases"
                },
                {
                    "id": "D000004701",
                    "term": "Endocrine Gland Neoplasms"
                },
                {
                    "id": "D000010182",
                    "term": "Pancreatic Diseases"
                },
                {
                    "id": "D000004700",
                    "term": "Endocrine System Diseases"
                },
                {
                    "id": "D000005831",
                    "term": "Genital Diseases, Female"
                },
                {
                    "id": "D000052776",
                    "term": "Female Urogenital Diseases"
                },
                {
                    "id": "D000005261",
                    "term": "Female Urogenital Diseases and Pregnancy Complications"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000005833",
                    "term": "Genital Neoplasms, Female"
                },
                {
                    "id": "D000014565",
                    "term": "Urogenital Neoplasms"
                },
                {
                    "id": "D000091662",
                    "term": "Genital Diseases"
                },
                {
                    "id": "D000018204",
                    "term": "Neoplasms, Connective and Soft Tissue"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000014594",
                    "term": "Uterine Neoplasms"
                },
                {
                    "id": "D000014591",
                    "term": "Uterine Diseases"
                },
                {
                    "id": "D000009385",
                    "term": "Neoplastic Processes"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5220",
                    "name": "Breast Neoplasms",
                    "asFound": "Breast Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M14850",
                    "name": "Recurrence",
                    "relevance": "LOW"
                },
                {
                    "id": "M12974",
                    "name": "Ovarian Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M13110",
                    "name": "Pancreatic Neoplasms",
                    "asFound": "Pancreatic Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6338",
                    "name": "Colonic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M15327",
                    "name": "Sarcoma",
                    "asFound": "Soft Tissue Sarcoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M17890",
                    "name": "Colorectal Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M12307",
                    "name": "Neoplasm Metastasis",
                    "asFound": "Metastatic Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M14846",
                    "name": "Rectal Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M25642",
                    "name": "Gastrointestinal Stromal Tumors",
                    "relevance": "LOW"
                },
                {
                    "id": "M30373",
                    "name": "Triple Negative Breast Neoplasms",
                    "asFound": "Triple Negative Breast Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1704",
                    "name": "Carcinoma, Ovarian Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M19235",
                    "name": "Endometrial Neoplasms",
                    "asFound": "Endometrial Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5218",
                    "name": "Breast Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M7256",
                    "name": "Digestive System Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M8886",
                    "name": "Gastrointestinal Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M7255",
                    "name": "Digestive System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8883",
                    "name": "Gastrointestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M7863",
                    "name": "Endocrine Gland Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M13102",
                    "name": "Pancreatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M7862",
                    "name": "Endocrine System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8943",
                    "name": "Genital Diseases, Female",
                    "relevance": "LOW"
                },
                {
                    "id": "M2876",
                    "name": "Genital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27093",
                    "name": "Female Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14127",
                    "name": "Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M8399",
                    "name": "Female Urogenital Diseases and Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M8945",
                    "name": "Genital Neoplasms, Female",
                    "relevance": "LOW"
                },
                {
                    "id": "M17315",
                    "name": "Urogenital Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M20350",
                    "name": "Neoplasms, Connective and Soft Tissue",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M17342",
                    "name": "Uterine Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M17339",
                    "name": "Uterine Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M12330",
                    "name": "Neoplastic Processes",
                    "relevance": "LOW"
                },
                {
                    "id": "T4387",
                    "name": "Pancreatic Cancer",
                    "asFound": "Pancreatic Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "T4352",
                    "name": "Ovarian Cancer",
                    "asFound": "Ovarian Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "T5284",
                    "name": "Soft Tissue Sarcoma",
                    "asFound": "Soft Tissue Sarcoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T2444",
                    "name": "Gastrointestinal Stromal Tumors",
                    "relevance": "LOW"
                },
                {
                    "id": "T4354",
                    "name": "Ovarian Epithelial Cancer",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                },
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000093542",
                    "term": "Gemcitabine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000964",
                    "term": "Antimetabolites, Antineoplastic"
                },
                {
                    "id": "D000000963",
                    "term": "Antimetabolites"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M2985",
                    "name": "Gemcitabine",
                    "asFound": "Mg/kg",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4281",
                    "name": "Antimetabolites",
                    "relevance": "LOW"
                },
                {
                    "id": "T120",
                    "name": "Cola",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "HB",
                    "name": "Herbal and Botanical"
                }
            ]
        }
    },
    "hasResults": false
}